Botanix Featured in AFR
Health Editor for The Australian Financial Review, Michael Smith, has featured Botanix Pharmaceuticals in an article titled The five pharma stocks exciting investors.
Smith speaks to leading fund managers about their experiences and professional insights when navigating the biotechnology sector – which they say is back in favour for those willing to sort the ‘winners from the losers’ and ride the wave of success stories like CSL.
Here is an excerpt, quoting Rory Hunter, a portfolio manager for SG Hiscock’s Medical Technology Fund:
‘“It requires a diversified approach to the sector. Once the IP is validated, you are moving into commercialisation and past regulatory approvals.”
‘He likes Botanix for this reason. Its treatment for hyperhidrosis, or severe underarm sweating, affects a large part of the population, and its Japanese partner has already commercialised its treatment. “They will accelerate revenues and profitability. While their IP isn’t quite as exciting, the market they are addressing is significant,” he says.’
